Ketoconazole Esteve

Ketoconazole, the active ingredient in Ketoconazole Esteve, is an imidazole antifungal presented as an oral formulation for systemic use. It inhibits fungal sterol synthesis and is employed to treat systemic mycoses such as blastomycosis, histoplasmosis and coccidioidomycosis, as well as dermatophytosis and seborrheic dermatitis in adult patients.

GNH USA supplies Ketoconazole Esteve as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable logistics for global distribution throughout.

Ketoconazole is an imidazole antifungal that acts on a broad spectrum of fungal pathogens.

- Systemic fungal infections: Effective in treating blastomycosis, histoplasmosis and coccidioidomycosis. - Dermatophytosis: Reduces skin lesions caused by dermatophyte species. - Seborrheic dermatitis: Controls Malassezia‑related scalp and skin inflammation.

Ketoconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset. - Headache: transient cranial pain. - Abdominal pain: discomfort in the stomach area. - Diarrhea: loose stools. - Rash: skin irritation or redness. - Elevated liver enzymes: mild hepatic enzyme increase.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury or failure. - Severe allergic reaction: anaphylaxis, swelling, or breathing difficulty. - QT prolongation: cardiac rhythm disturbance. - Thrombocytopenia: low platelet count. - Stevens‑Johnson syndrome: severe skin blistering. - Adrenal insufficiency: cortisol production impairment.

Before prescribing ketoconazole, clinicians should consider several precautionary measures to minimize risk. - Liver function monitoring: assess baseline and periodic hepatic enzymes. - Drug interactions review: evaluate concomitant use of CYP3A4 substrates. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Pre‑existing cardiac conditions: monitor QT interval in at‑risk patients. - Alcohol consumption: advise limiting alcohol to reduce hepatotoxic risk. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Ketoconazole interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - CYP3A4 substrates: increased plasma levels of drugs such as midazolam, cyclosporine. - Statins (lovastatin, simvastatin): heightened risk of myopathy and rhabdomyolysis. - Anticoagulants (warfarin): potentiated anticoagulant effect.

Moderate Interactions (Monitor Closely): - CYP2C9 substrates: altered levels of drugs like phenytoin. - Hormonal contraceptives: reduced efficacy, consider backup method. - QT‑prolonging agents: additive risk of cardiac arrhythmia.